·A Retrospective Cohort Study of the Efficacy and Safety of Oral Azvudine Versus Paxlovid in Elderly Hospitalized COVID-19 Patients Aged Over 60 Years DOI

Bo Yu,

Haiyu Wang, Guangming Li

et al.

Published: Jan. 1, 2024

Background: COVID-19 has caused a great test to people's life safety, especially for the elderly group over 60 years old. Azvudine and Paxlovid were widely used as anti-COVID-19 drugs in clinical treatment during first Omicron wave China. Herein, we aimed compare efficacy safety of two population.Methods: In this retrospective study conducted at nine hospitals Henan Province, China, total 5131 hospitalized patients included from December 5, 2022, January 31, 2023. The main focus was on all-cause mortality composite disease progression. Comparative evaluations carried out between groups using Kaplan–Meier Cox regression methods. To ensure reliability results, subgroup sensitivity analyses employed.Results: Following exclusions propensity score matching, 1769 treated with 892 selected. analysis revealed had higher risk death (HR: 1.33, 95% CI: 1.066-1.663, p=0.01) versus group, but no difference progression 0.9, 0.752-1.082, p=0.26). Notably, compared without primary malignant tumors, exhibited 2.69, 1.39−5.21, p=0.037) tumors. robustness these findings confirmed through three analyses.Interpretation: results suggest that among have lower fewer adverse effects.Trial Registration: This also completed registration ClinicalTrials under clinicaltrial number NCT06349655. Funding: work supported by National Key Research Development Program China (2022YFC2303100 Z.R.). Province Epidemic Prevention Control Emergency Scientific Project (221111311700 Z.R.), Central Plains Talent Program-Central Youth Top Talents Z.R., Young Middleaged Academic Leaders Provincial Health Commission (HNSWJW-2022013 Innovation Team First Affiliated Hospital Zhengzhou University (QNCXTD2023002 Declaration Interest: authors declare conflict interestEthical Approval: endorsed research ethics committee AffiliatedHospital authorized approval 2023-KY0865-001.

Language: Английский

The Significance of Endothelial Dysfunction in Long COVID-19 for the Possible Future Pandemic of Chronic Kidney Disease and Cardiovascular Disease DOI Creative Commons
Hidekatsu Yanai,

Hiroki Adachi,

Mariko Hakoshima

et al.

Biomolecules, Journal Year: 2024, Volume and Issue: 14(8), P. 965 - 965

Published: Aug. 8, 2024

Various symptoms have been reported to persist beyond the acute phase of severe respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, which is referred as long disease 19 (long COVID-19). Over 65 million individuals suffer from COVID-19. However, causes COVID-19 are largely unknown. Since observed throughout body, vascular endothelial dysfunction a strong candidate explaining induction The angiotensin-converting enzyme (ACE2), entry receptor for SARS-CoV-2, ubiquitously expressed in cells. We previously found that risk factors atherosclerotic cardiovascular (ASCVD) and history ASCVD raise COVID-19, suggesting contribution pre-existing Here, we show significant association with development biomarkers patients also crucial players ASCVD. consider influence on chronic kidney (CKD) Future assessments outcomes resulting therapeutic interventions improve function may imply significance

Language: Английский

Citations

1
·A Retrospective Cohort Study of the Efficacy and Safety of Oral Azvudine Versus Paxlovid in Elderly Hospitalized COVID-19 Patients Aged Over 60 Years DOI

Bo Yu,

Haiyu Wang, Guangming Li

et al.

Published: Jan. 1, 2024

Background: COVID-19 has caused a great test to people's life safety, especially for the elderly group over 60 years old. Azvudine and Paxlovid were widely used as anti-COVID-19 drugs in clinical treatment during first Omicron wave China. Herein, we aimed compare efficacy safety of two population.Methods: In this retrospective study conducted at nine hospitals Henan Province, China, total 5131 hospitalized patients included from December 5, 2022, January 31, 2023. The main focus was on all-cause mortality composite disease progression. Comparative evaluations carried out between groups using Kaplan–Meier Cox regression methods. To ensure reliability results, subgroup sensitivity analyses employed.Results: Following exclusions propensity score matching, 1769 treated with 892 selected. analysis revealed had higher risk death (HR: 1.33, 95% CI: 1.066-1.663, p=0.01) versus group, but no difference progression 0.9, 0.752-1.082, p=0.26). Notably, compared without primary malignant tumors, exhibited 2.69, 1.39−5.21, p=0.037) tumors. robustness these findings confirmed through three analyses.Interpretation: results suggest that among have lower fewer adverse effects.Trial Registration: This also completed registration ClinicalTrials under clinicaltrial number NCT06349655. Funding: work supported by National Key Research Development Program China (2022YFC2303100 Z.R.). Province Epidemic Prevention Control Emergency Scientific Project (221111311700 Z.R.), Central Plains Talent Program-Central Youth Top Talents Z.R., Young Middleaged Academic Leaders Provincial Health Commission (HNSWJW-2022013 Innovation Team First Affiliated Hospital Zhengzhou University (QNCXTD2023002 Declaration Interest: authors declare conflict interestEthical Approval: endorsed research ethics committee AffiliatedHospital authorized approval 2023-KY0865-001.

Language: Английский

Citations

0